FGF2's Role in Non-GIST Soft Tissue Sarcomas
Author Information
Author(s): Kilvaer Thomas K, Valkov Andrej, Sorbye Sveinung W, Smeland Eivind, Bremnes Roy M, Busund Lill-Tove, Donnem Tom
Primary Institution: University of Tromso
Hypothesis
This study investigates the prognostic impact of FGF2 and FGFR-1 and explores the impact of their co-expression with PDGF-B and VEGFR-3 in widely resected tumors from non-GIST STS patients.
Conclusion
High expression of FGF2 and its co-expressions with PDGF-B and VEGFR-3 are significant independent negative prognostic factors in widely resected non-GIST STS patients.
Supporting Evidence
- High expression of FGF2 was significantly associated with a poor prognosis.
- Co-expressions of FGF2 & PDGF-B and FGF2 & VEGFR-3 were significant independent prognostic indicators of poor disease-specific survival.
- Russian nationality and high malignancy grade were also significant negative indicators of disease-specific survival.
Takeaway
This study found that a protein called FGF2 can help predict how well patients with certain tumors will do after treatment.
Methodology
Tumor samples from 108 non-GIST STS patients were obtained, and immunohistochemistry was used to evaluate the expressions of FGF-2, FGFR-1, PDGF-B, and VEGFR-3.
Potential Biases
Potential bias may arise from the retrospective nature of the study and the reliance on previously collected clinical data.
Limitations
The study is limited by its retrospective design and the exclusion of patients with missing clinical data.
Participant Demographics
The median age was 57 years, with 56% female participants; 73 patients were Norwegian and 35 were Russian.
Statistical Information
P-Value
0.024
Confidence Interval
95% CI 1.1-4.4
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website